These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 36329392)
1. The effect of vitreomacular interface in neovascular age-related macular degeneration treated with intravitreal injection of anti-VEGF. Han F; Chen X; Zhao R; Jin X; Tan W; Zhang Y BMC Ophthalmol; 2022 Nov; 22(1):419. PubMed ID: 36329392 [TBL] [Abstract][Full Text] [Related]
3. The incidence and risk factors for the development of vitreomacular interface abnormality in diabetic macular edema treated with intravitreal injection of anti-VEGF. Chang CK; Cheng CK; Peng CH Eye (Lond); 2017 May; 31(5):762-770. PubMed ID: 28106889 [TBL] [Abstract][Full Text] [Related]
4. Vitreomacular interface abnormalities in patients with diabetic macular oedema and their implications on the response to anti-VEGF therapy. Mikhail M; Stewart S; Seow F; Hogg R; Lois N Graefes Arch Clin Exp Ophthalmol; 2018 Aug; 256(8):1411-1418. PubMed ID: 29779188 [TBL] [Abstract][Full Text] [Related]
5. Influence of vitreomacular interface on anti-vascular endothelial growth factor treatment outcomes in neovascular age-related macular degeneration: A MOOSE-compliant meta-analysis. Gao M; Liu L; Liang X; Yu Y; Liu X; Liu W Medicine (Baltimore); 2017 Dec; 96(50):e9345. PubMed ID: 29390407 [TBL] [Abstract][Full Text] [Related]
6. Influence of the vitreomacular interface on outcomes of ranibizumab therapy in neovascular age-related macular degeneration. Mayr-Sponer U; Waldstein SM; Kundi M; Ritter M; Golbaz I; Heiling U; Papp A; Simader C; Schmidt-Erfurth U Ophthalmology; 2013 Dec; 120(12):2620-2629. PubMed ID: 23870300 [TBL] [Abstract][Full Text] [Related]
7. Effects of vitreomacular adhesion on anti-vascular endothelial growth factor treatment for exudative age-related macular degeneration. Lee SJ; Koh HJ Ophthalmology; 2011 Jan; 118(1):101-10. PubMed ID: 20678805 [TBL] [Abstract][Full Text] [Related]
8. Influence of the vitreomacular interface on the efficacy of intravitreal therapy for uveitis-associated cystoid macular oedema. Munk MR; Ram R; Rademaker A; Liu D; Setlur V; Chau F; Schmidt-Erfurth U; Goldstein DA Acta Ophthalmol; 2015 Nov; 93(7):e561-7. PubMed ID: 25708777 [TBL] [Abstract][Full Text] [Related]
9. Evaluating the effect of vitreomacular interface abnormalities on anti-vascular endothelial growth factor treatment outcomes in diabetic macular edema by optical coherence tomography: A systematic review and meta-analysis. Gong Y; Wang M; Li Q; Shao Y; Li X Photodiagnosis Photodyn Ther; 2023 Jun; 42():103555. PubMed ID: 37088331 [TBL] [Abstract][Full Text] [Related]
16. THE INFLUENCE OF VITREOMACULAR ADHESION ON OUTCOMES AFTER AFLIBERCEPT THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. McKibbin MA; Suter CA; Willis TA Retina; 2015 Oct; 35(10):1951-6. PubMed ID: 25932561 [TBL] [Abstract][Full Text] [Related]
17. Impact of vitreomacular adhesion on ranibizumab mono- and combination therapy for neovascular age-related macular degeneration. Waldstein SM; Ritter M; Simader C; Mayr-Sponer U; Kundi M; Schmidt-Erfurth U Am J Ophthalmol; 2014 Aug; 158(2):328-336.e1. PubMed ID: 24794282 [TBL] [Abstract][Full Text] [Related]
18. INFLUENCE OF VITREOMACULAR INTERFACE ON ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY USING TREAT AND EXTEND TREATMENT PROTOCOL FOR AGE-RELATED MACULAR DEGENERATION (VINTREX). Houston SK; Rayess N; Cohen MN; Ho AC; Regillo CD Retina; 2015 Sep; 35(9):1757-64. PubMed ID: 26110596 [TBL] [Abstract][Full Text] [Related]
20. The prevalence of vitreomacular adhesion in eyes with macular oedema secondary to retinal vein occlusion selected for intravitreal injections. Maggio E; Maraone G; Mete M; Vingolo EM; Grenga PL; Guerriero M; Pertile G Acta Ophthalmol; 2021 Nov; 99(7):e1154-e1161. PubMed ID: 33421346 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]